BioNTech reported third quarter 2026 revenue of €1.29 billion, significantly outperforming consensus estimates of €1.04 billion. The performance was largely driven by the company's collaboration with Bristol Myers Squibb related to the pumitamig program, which helped offset the anticipated decline in COVID-19 vaccine demand. Consequently, the company raised the midpoint of its full-year 2026 revenue guidance to a range of €1.7 billion to €1.9 billion.
Key Highlights
- Total revenue of €1.29 billion beat analyst estimates by approximately 24%.
- Full-year 2026 revenue guidance range was narrowed and the midpoint raised to €1.8 billion from roughly €1.75 billion.
- Maintained a strong financial position with €16.2 billion in cash, cash equivalents, and security investments.
- Advanced oncology pipeline with the initiation of a global Phase 3 trial evaluating pumitamig in combination with Gilead’s sacituzumab govitecan.